DK1891961T3 - Anvendelse af 5'-methylthioadenosin (MTA) i forebyggelsen og/eller behandling af autoimmune sygdomme og/eller transplantatafstödning - Google Patents

Anvendelse af 5'-methylthioadenosin (MTA) i forebyggelsen og/eller behandling af autoimmune sygdomme og/eller transplantatafstödning

Info

Publication number
DK1891961T3
DK1891961T3 DK05728461T DK05728461T DK1891961T3 DK 1891961 T3 DK1891961 T3 DK 1891961T3 DK 05728461 T DK05728461 T DK 05728461T DK 05728461 T DK05728461 T DK 05728461T DK 1891961 T3 DK1891961 T3 DK 1891961T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
methylthioadenosine
mta
autoimmune diseases
Prior art date
Application number
DK05728461T
Other languages
Danish (da)
English (en)
Inventor
Garcia-Trevijano Elena Ruiz
Diaz Pablo Villoslada
Zaragoza Matyas Avila
Bruna Beatriz Moreno
Izquierdo Fernando Corrales
Lasarte Carmen Berasain
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Application granted granted Critical
Publication of DK1891961T3 publication Critical patent/DK1891961T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK05728461T 2005-03-17 2005-03-17 Anvendelse af 5'-methylthioadenosin (MTA) i forebyggelsen og/eller behandling af autoimmune sygdomme og/eller transplantatafstödning DK1891961T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2005/000139 WO2006097547A1 (es) 2005-03-17 2005-03-17 Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes

Publications (1)

Publication Number Publication Date
DK1891961T3 true DK1891961T3 (da) 2009-12-21

Family

ID=36991307

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05728461T DK1891961T3 (da) 2005-03-17 2005-03-17 Anvendelse af 5'-methylthioadenosin (MTA) i forebyggelsen og/eller behandling af autoimmune sygdomme og/eller transplantatafstödning

Country Status (19)

Country Link
US (1) US7820637B2 (pl)
EP (1) EP1891961B1 (pl)
JP (1) JP2008533107A (pl)
CN (1) CN101141970A (pl)
AT (1) ATE442854T1 (pl)
AU (1) AU2005329287B2 (pl)
BR (1) BRPI0520129A2 (pl)
CA (1) CA2601557A1 (pl)
CY (1) CY1109539T1 (pl)
DE (1) DE602005016729D1 (pl)
DK (1) DK1891961T3 (pl)
ES (1) ES2334924T3 (pl)
HR (1) HRP20090646T1 (pl)
MX (1) MX2007011327A (pl)
PL (1) PL1891961T3 (pl)
PT (1) PT1891961E (pl)
RS (1) RS51122B (pl)
SI (1) SI1891961T1 (pl)
WO (1) WO2006097547A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329327B1 (es) 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
CN102573854A (zh) * 2009-06-11 2012-07-11 普罗耶克托生物医学Cima有限公司 5’-甲硫腺苷的神经保护特性
WO2011054990A2 (es) * 2009-11-05 2011-05-12 Proyecto De Biomedicina Cima, S.L. Composiciones para la inhibición y/o bloqueo de la transición epitelial-mesenquimal
JP5801572B2 (ja) * 2011-03-03 2015-10-28 シーシーアイ株式会社 ＰＰＡＲγ活性化剤
CN105153042B (zh) * 2015-07-17 2017-11-24 四川大学 一种化合物及其在制备治疗可卡因成瘾的药物中的用途
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
WO2020206299A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
CN114515294A (zh) 2022-02-25 2022-05-20 浙江中医药大学 5’-甲基硫代腺苷在制备肥胖抑制药物或保健品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1193529B (it) * 1980-04-22 1988-07-08 Bioresearch Srl Derivati adenosinici ad attivita' antinfiammatoria ed analgesica e composizioni terapeutiche che li contengono come principio attivo
IT1227049B (it) * 1988-07-29 1991-03-14 Bioresearch Spa Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
ATE271063T1 (de) * 1996-10-16 2004-07-15 Icn Pharmaceuticals Purin-l-nukleoside, deren analoga und verwendungen
CA2306811A1 (en) * 1997-10-14 1999-04-22 Yoshiyuki Aoki Piperazine compounds and medicinal use thereof
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
JP2001072660A (ja) * 1999-09-08 2001-03-21 Welfide Corp ＴＮＦ−α産生抑制剤および／またはＩＬ−１０産生促進剤
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
AU2001241067A1 (en) * 2000-03-09 2001-09-17 Ono Pharmaceutical Co. Ltd. Omega-substituted phenyl-prostaglandin e-alcohols, process for producing the same and drugs containing the same as the active ingredient
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes

Also Published As

Publication number Publication date
RS51122B (sr) 2010-10-31
SI1891961T1 (sl) 2010-01-29
MX2007011327A (es) 2008-01-28
US7820637B2 (en) 2010-10-26
AU2005329287B2 (en) 2011-01-27
EP1891961A1 (en) 2008-02-27
EP1891961B1 (en) 2009-09-16
DE602005016729D1 (de) 2009-10-29
ES2334924T3 (es) 2010-03-17
HRP20090646T1 (hr) 2010-01-31
AU2005329287A1 (en) 2006-09-21
PT1891961E (pt) 2009-12-17
ATE442854T1 (de) 2009-10-15
PL1891961T3 (pl) 2010-02-26
CY1109539T1 (el) 2014-08-13
US20090042831A1 (en) 2009-02-12
JP2008533107A (ja) 2008-08-21
CA2601557A1 (en) 2006-09-21
BRPI0520129A2 (pt) 2009-04-28
CN101141970A (zh) 2008-03-12
WO2006097547A1 (es) 2006-09-21

Similar Documents

Publication Publication Date Title
DK1891961T3 (da) Anvendelse af 5'-methylthioadenosin (MTA) i forebyggelsen og/eller behandling af autoimmune sygdomme og/eller transplantatafstödning
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
BR0311285A (pt) composições e processos para revestimento de implantes médicos
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DK1663185T3 (da) Forebyggelse og behandling af inflammationsinduceret og/eller immun-medieret knogletab
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
ATE407967T1 (de) Nukleierungsmittel
AR050717A1 (es) Composiciones farmaceuticas
WO2006034001A3 (en) Methods of treating hiv infection
WO2007037849A3 (en) Compositions and methods for the intraocular transport of therapeutic agents
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
WO2007059226A3 (en) Photoactivatable antimicrobial agents
TW200716088A (en) Formulations and methods for treating amyloidosis
RS50981B (sr) Fosfoindoli kao hiv inhibitori
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
WO2004091436A3 (en) Methods and compositions for treating ocular disease
FR2872431B1 (fr) Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire
DK1606233T3 (da) Phospholipidestere af Clofarabin
WO2006079121A3 (en) Methods of treating disease with glycosylated interferon
SE0500291L (sv) New composition and the use thereof
WO2006060172A3 (en) Methods for identifying graft rejection suppressing compounds
MY157231A (en) Aminocyclohexyl ether compounds and uses thereof